Licensed, profitable German medical cannabis importer & wholesaler for sale on target for €8M/yr revenue

This is a fully operational, profitable medical cannabis importer & wholesaler with established distribution across the German market, the single largest and most valuable medical cannabis market in Europe.

The company is a solid revenue-generator, on target to reach €8 million in 2025, with €10.8 Million in revenue projected for 2026.

The platform provides direct, regulatory-compliant market access, leveraging established EU-GDP and EU-GMP supply chains and a trusted network of 40 global suppliers for broad-based product sourcing.

The company distributes a diverse product portfolio (+50 products across +35 strains), including its own proprietary brands.

The company is actively pending EU-GMP manufacturing certification which will provide a clear, de-risked pathway to internal processing and product manufacturing, allowing the capture of higher-margin activities.

The company is led by an experienced management team with deep roots in the German pharmaceutical and pharmacy markets.

The R&D pipeline focuses on high-value product innovation, including access to an innovative lozenge formulation and specialized oral administration solutions, securing a future competitive advantage.

The business is highly scalable, successfully managing high-volume sales (over 2.5 tonnes annually) with a minimal workforce (15 FTEs), ready for increased throughput upon capital injection.

The acquisition secures access to a patented purification technology, ensuring a proprietary, cost-efficient supply chain of pharmaceutical-grade, EU-GMP certified product starting in 2026.

This opportunity is ideal for Global Cannabis Operators, Healthcare/Pharma Players, and Investment Firms seeking immediate, de-risked entry and a high-growth platform within the regulated German and European medical cannabis markets.